ObsEva (OBSV) Competitors

OBSV vs. RNTX, HOWL, SNTI, LSTA, and BCTX

Should you buy ObsEva stock or one of its competitors? MarketBeat compares ObsEva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ObsEva include Rein Therapeutics (RNTX), Werewolf Therapeutics (HOWL), Senti Biosciences (SNTI), Lisata Therapeutics (LSTA), and Briacell Therap (BCTX). These companies are all part of the "pharmaceutical products" industry.

How does ObsEva compare to Rein Therapeutics?

ObsEva (NASDAQ:OBSV) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

In the previous week, ObsEva's average media sentiment score of 0.00 equaled Rein Therapeutics'average media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
Rein Therapeutics	Neutral

ObsEva's return on equity of -416.36% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Rein Therapeutics	N/A	-510.35%	-68.14%

Rein Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 676.70%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rein Therapeutics is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rein Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Summary

Rein Therapeutics beats ObsEva on 7 of the 11 factors compared between the two stocks.

How does ObsEva compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Werewolf Therapeutics had 4 more articles in the media than ObsEva. MarketBeat recorded 4 mentions for Werewolf Therapeutics and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.29 indicating that ObsEva is being referred to more favorably in the news media.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
ObsEva	Neutral

ObsEva has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	11.47	-$60.82M	-$1.24	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Werewolf Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Werewolf Therapeutics currently has a consensus target price of $3.75, suggesting a potential upside of 745.36%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Werewolf Therapeutics' return on equity of -208.23% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
ObsEva	N/A	-416.36%	-92.01%

Summary

Werewolf Therapeutics beats ObsEva on 9 of the 14 factors compared between the two stocks.

How does ObsEva compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Senti Biosciences had 8 more articles in the media than ObsEva. MarketBeat recorded 8 mentions for Senti Biosciences and 0 mentions for ObsEva. ObsEva's average media sentiment score of 0.00 beat Senti Biosciences' score of -1.00 indicating that ObsEva is being referred to more favorably in the news media.

Company	Overall Sentiment
Senti Biosciences	Negative
ObsEva	Neutral

ObsEva has lower revenue, but higher earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,537.10	-$61.44M	-$1.92	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

ObsEva's return on equity of -416.36% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
ObsEva	N/A	-416.36%	-92.01%

Senti Biosciences has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Senti Biosciences presently has a consensus price target of $8.75, suggesting a potential upside of 786.61%. Given Senti Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Senti Biosciences is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Senti Biosciences beats ObsEva on 8 of the 15 factors compared between the two stocks.

How does ObsEva compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

In the previous week, Lisata Therapeutics had 2 more articles in the media than ObsEva. MarketBeat recorded 2 mentions for Lisata Therapeutics and 0 mentions for ObsEva. Lisata Therapeutics' average media sentiment score of 1.55 beat ObsEva's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Very Positive
ObsEva	Neutral

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lisata Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Lisata Therapeutics' return on equity of -103.54% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
ObsEva	N/A	-416.36%	-92.01%

Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 377.71%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lisata Therapeutics is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Lisata Therapeutics has higher revenue and earnings than ObsEva. Lisata Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	168.27	-$16.59M	-$1.86	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Summary

Lisata Therapeutics beats ObsEva on 9 of the 13 factors compared between the two stocks.

How does ObsEva compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Briacell Therap's return on equity of -173.08% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
ObsEva	N/A	-416.36%	-92.01%

Given ObsEva's higher probable upside, analysts clearly believe ObsEva is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Briacell Therap is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Briacell Therap has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Briacell Therap had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for Briacell Therap and 0 mentions for ObsEva. Briacell Therap's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
Briacell Therap	Neutral
ObsEva	Neutral

Summary

ObsEva beats Briacell Therap on 6 of the 11 factors compared between the two stocks.

Get ObsEva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBSV vs. The Competition

Export

Metric	ObsEva	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.94M	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	0.00	1.46	21.00	25.66
Price / Sales	N/A	119.63	562.18	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	N/A	7.59	10.41	7.14
Net Income	-$58.38M	-$3.64M	$3.57B	$335.98M

ObsEva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
RNTX Rein Therapeutics	2.5415 of 5 stars	$1.16 +3.6%	$8.00 +589.7%	-49.8%	$31.40M	N/A	N/A	9
HOWL Werewolf Therapeutics	3.05 of 5 stars	$0.58 -7.6%	$3.75 +542.2%	-61.4%	$30.71M	$1.88M	N/A	40	Gap Down High Trading Volume
SNTI Senti Biosciences	2.2705 of 5 stars	$0.96 -0.7%	$8.50 +782.7%	-69.2%	$30.21M	$20K	N/A	4	Negative News
LSTA Lisata Therapeutics	2.2511 of 5 stars	$3.28 +0.6%	$15.00 +357.3%	+18.9%	$29.69M	$170K	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBSV) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ObsEva (OBSV) Competitors

OBSV vs. RNTX, HOWL, SNTI, LSTA, and BCTX

How does ObsEva compare to Rein Therapeutics?

Summary

How does ObsEva compare to Werewolf Therapeutics?

Summary

How does ObsEva compare to Senti Biosciences?

Summary

How does ObsEva compare to Lisata Therapeutics?

Summary

How does ObsEva compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ObsEva (OBSV) Competitors

OBSV vs. RNTX, HOWL, SNTI, LSTA, and BCTX

How does ObsEva compare to Rein Therapeutics?

Does the media refer more to OBSV or RNTX?

Is OBSV or RNTX more profitable?

Do analysts rate OBSV or RNTX?

Which has stronger earnings & valuation, OBSV or RNTX?

Do institutionals & insiders hold more shares of OBSV or RNTX?

Which has more risk and volatility, OBSV or RNTX?

Summary

How does ObsEva compare to Werewolf Therapeutics?

Do institutionals and insiders have more ownership in HOWL or OBSV?

Does the media prefer HOWL or OBSV?

Which has stronger earnings & valuation, HOWL or OBSV?

Which has more risk & volatility, HOWL or OBSV?

Do analysts rate HOWL or OBSV?

Is HOWL or OBSV more profitable?

Summary

How does ObsEva compare to Senti Biosciences?

Does the media favor SNTI or OBSV?

Which has better valuation & earnings, SNTI or OBSV?

Is SNTI or OBSV more profitable?

Which has more volatility & risk, SNTI or OBSV?

Do insiders and institutionals have more ownership in SNTI or OBSV?

Do analysts rate SNTI or OBSV?

Summary

How does ObsEva compare to Lisata Therapeutics?

Does the media refer more to LSTA or OBSV?

Do insiders & institutionals have more ownership in LSTA or OBSV?

Which has more volatility and risk, LSTA or OBSV?

Is LSTA or OBSV more profitable?

Do analysts recommend LSTA or OBSV?

Which has stronger earnings and valuation, LSTA or OBSV?

Summary

How does ObsEva compare to Briacell Therap?

Do insiders and institutionals believe in BCTX or OBSV?

Is BCTX or OBSV more profitable?

Do analysts prefer BCTX or OBSV?

Which has preferable earnings & valuation, BCTX or OBSV?

Which has more volatility and risk, BCTX or OBSV?

Does the media favor BCTX or OBSV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools